TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07135973: A Multi-center, Single-arm Phase IV Clinical Trial to Evaluate the Safety of Belumosudil in Indian Participants, 12 Years and Above, With Chronic Graft-versus-host Disease (cGVHD)

Sponsor: Sanofi · Phase: PHASE4 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 26 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$4,355,840

Rescue Site Savings

+$2,868,480

Unlock Full NCT07135973 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07135973 Rescue Dossier →